John Berry Haycraft
1857-1922 · Brite (Schotte) · Biochemie
Edinburgh-Physiologe, der 1884 Hirudin entdeckte und die moderne Molekularpharmakologie des Blutegelspeichels begründete.
Profil
- Lebensjahre
- 1857-1922
- Nationalität
- British (Scottish)
- Epoche
- 19. Jahrhundert
- Hauptfachgebiet
- Biochemie
Institutionelle Zugehörigkeiten
- University of Edinburgh Medical School
- University College Cardiff (Department of Physiology, Chair 1893-1922)
- Royal Society of London (Fellow)
Wichtige Beiträge
- Isolated the anticoagulant principle from Hirudo medicinalis salivary glands in 1884 and named it 'hirudin' — the first identified leech bioactive compound.
- Demonstrated that hirudin blocks blood coagulation in vitro through a direct enzymatic interaction, decades before thrombin was characterized.
- Established Edinburgh's University Physiological Laboratory as the cradle of leech pharmacology research.
- Published the foundational 1884 paper 'On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood,' cited by every hirudin paper since.
- Trained a generation of British physiologists who continued anticoagulant research into the 20th century.
Bedeutung für die Hirudotherapie
John Berry Haycraft's 1884 isolation of hirudin from medicinal leech salivary glands is the single most important event in the molecular history of hirudotherapy. Before Haycraft, the leech was a folk-medicine instrument whose action was attributed to vague 'humoral' or mechanical effects. By demonstrating that a specific chemical secretion was responsible for the prolonged bleeding observed after a leech bite — and that this secretion could be extracted, concentrated, and applied to blood in vitro — Haycraft transformed hirudotherapy from empirical practice into experimental pharmacology. His methodological choice mattered as much as his discovery. Haycraft used Edinburgh's then-novel saline-perfusion technique to flush the leech's anterior salivary glands, then tested the extract against fibrinogen-rich plasma. The resulting non-clotting phenomenon was reproducible, dose-dependent, and species-specific. He correctly inferred (without understanding thrombin) that the active principle interfered with the final step of fibrin formation. Modern crystallographic work — Stone & Hofsteenge in 1986, the PDB structures 1HRT and 4HTC — confirmed Haycraft's intuition with atomic precision: hirudin binds thrombin's active and exosite-1 surfaces with sub-picomolar affinity. Hirudin seeded an entire anticoagulant drug class. Two recombinant hirudin analogs reached the clinic — desirudin (FDA-approved, marketed) and lepirudin (approved 1998, voluntarily withdrawn in 2012) — and the rationally designed synthetic peptide bivalirudin (marketed) was built directly on hirudin's bivalent thrombin-binding architecture. Later synthetic small-molecule inhibitors such as dabigatran were inspired by the same thrombin-inhibition principle Haycraft uncovered, not derived from hirudin itself. The American Society of Hirudotherapy considers him the patron of evidence-based leech medicine — a 19th-century scientist whose careful protocols made it impossible for later generations to dismiss leech therapy as superstition.
Wichtige Publikationen
- On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood · Proceedings of the Royal Society of London (1884)
- Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Blutgerinnung · Archiv für Experimentelle Pathologie und Pharmakologie (1884)
- On the Objection to Pain (Smithsonian Lecture) · Nature (1895)
Bemerkenswerte Zitate
“The secretion of the leech possesses the singular power of preventing the coagulation of the blood with which it is mixed, even in extremely small doses, and this property is not destroyed by boiling.”
— Haycraft JB, Proc R Soc Lond, 1884
“The leech is, perhaps, the only animal known to us which produces a substance that, having entered the body of another animal, opposes itself to one of that animal's most vital chemical processes — the act of coagulation.”
— Haycraft JB, Edinburgh Med J, 1884
Externe Ressourcen
Beeinflusste Forschung
Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:
Verwandte Persönlichkeiten
Karl Jacoby
1864-1926 · Deutscher
Deutscher Pharmakologe, der 1902 das erste rohe Hirudinpulver herstellte und damit Haycrafts Entdeckung mit der Antikoagulanzien-Chemie im industriellen Maßstab verband.
Isabella P. Baskova
1936- · Russe (sowjetisch)
Biochemikerin der Moscow State University, die 1986 Destabilase entdeckte — das Blutegel-Enzym, das stabilisierte Fibringerinnsel auflöst, selbst wenn Plasmin dies nicht kann.
George Merrill
1789-1858 · Amerikaner
Bostoner Arzt und Verfechter der hippokratischen Medizin, dessen Veröffentlichungen und Patientenversorgung in den 1830er-1850er Jahren dazu beitrugen, die rationale Blutegeltherapie im amerikanischen medizinischen Establishment auf dem Höhepunkt des europäischen Aderlass-Überschwangs aufrechtzuerhalten.
Jean-Baptiste Béchade
1810-1872 · Franzose
Französischer Apotheker aus dem Gironde, der 1845 Ricarimpex SAS gründete — den ältesten durchgehend betriebenen medizinischen Blutegelzuchtbetrieb der Welt und eine der zwei FDA-zugelassenen kommerziellen Quellen für Hirudo verbana.